Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders held by Mirum Pharmaceuticals, Inc. on June 11, 2020. The record date for the meeting was April 22, 2020, with 25,389,987 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1: Election of Directors
- Tiba Aynechi, Ph.D.: Elected as Class I Director. Received 16,489,971 votes for, 558,188 votes withheld, and 1,946,985 broker non-votes.
- Edward T. Mathers: Elected as Class I Director. Received 16,418,105 votes for, 630,054 votes withheld, and 1,946,985 broker non-votes.
- Both directors will serve until the 2023 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Voting results: 18,989,072 votes for, 4,172 votes against, 1,900 abstentions, and no broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that Tiba Aynechi, Ph.D., and Edward T. Mathers were successfully elected to the Board of Directors.
- Verification that Ernst & Young LLP was ratified as the independent auditor for the 2020 fiscal year.
- Review of the high number of broker non-votes (1,946,985) on the director election proposal relative to the total shares outstanding.